Baxter and Onconova sign licensing agreement for anti-caner compound Rigosertib Baxter and Onconova Therapeutics, Inc. have entered into a European licensing agreement for rigosertib, a novel targeted anti-cancer compound currently in a Phase III study for the treatment of a group of rare hematologic malignancies called Myelodysplastic Syndromes and in a Phase II/III study for pancreatic cancer. Baxter will obtain commercialization rights in the European Union and other countries in Europe. Baxter will make an upfront payment of $50M to Onconova, which will be recorded as a special pre-tax in-process research and development charge in Q3.
News For BAX From The Last 14 Days
Check below for free stories on BAX the last two weeks.
Baxter granted authorization by European Commission for use of HyQvia Baxter International (BAX) and Halozyme Therapeutics (HALO) announced that the European Commission has granted Baxter marketing authorization in all European Union Member States for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxter will introduce HyQvia in select countries during 2013 and plans to expand the launch to other EU countries in 2014.